Sorafenib (BAY 43-9006, Nexavar®) is a new biaryl urea that shows anti-mytotic and anti-angiogenetic properties. It has recently been approved by the FDA (Food and Drug Administration) for advanced renal cell carcinoma in phase III clinical trials. In phase I and phase II clinical trials, sorafenib showed disease stabilization and few side effects [1]. We report a 79-year-old man on oral therapy with sorafenib 400 mg twice daily for metastatic renal cell carcinoma. After 20 days he developed painful erythematous plaques and bullae that evolved in skin erosions on his elbows, fi ngertips, and lower limbs.
Sorafenib: atypical cutaneous side effects / Richetta, Antonio Giovanni; E., Maiani; V., Carboni; V., Carlomagno; M., Cimillo; C., Mattozzi; Calvieri, Stefano. - In: EUROPEAN JOURNAL OF DERMATOLOGY. - ISSN 1167-1122. - 17:(2007), pp. 549-550.
Sorafenib: atypical cutaneous side effects
RICHETTA, Antonio Giovanni;CALVIERI, Stefano
2007
Abstract
Sorafenib (BAY 43-9006, Nexavar®) is a new biaryl urea that shows anti-mytotic and anti-angiogenetic properties. It has recently been approved by the FDA (Food and Drug Administration) for advanced renal cell carcinoma in phase III clinical trials. In phase I and phase II clinical trials, sorafenib showed disease stabilization and few side effects [1]. We report a 79-year-old man on oral therapy with sorafenib 400 mg twice daily for metastatic renal cell carcinoma. After 20 days he developed painful erythematous plaques and bullae that evolved in skin erosions on his elbows, fi ngertips, and lower limbs.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
